Drug Trial Radar · NCT05450692
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
594
Actual
Start
Sep 15, 2022
Primary completion
Oct 6, 2025
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Jul 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the efficacy and safety of the combination of ceralasertib and durvalumab versus standard of care docetaxel in patients with locally advanced and metastatic NSCLC after progression on prior anti-PD-(L)1 therapy and platinum-based chemotherapy.
Conditions
- Advanced or Metastatic Non-Small Cell Lung Cancer
Interventions
CeralasertibDrug
Participants will receive ceralasertib oral tablets.
DurvalumabDrug
Participants will receive durvalumab as an intravenous infusion.
DocetaxelDrug
Participants will received docetaxel as an intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Every 3 months (± 1 week) following objective progression of disease (PD) or treatment discontinuation (up to three years)
Locations
191 sites in 23 countries. Site status is shown where the registry gives one.
Research Site
Mobile, Alabama
Research Site
Chandler, Arizona
Research Site
Los Alamitos, California
Research Site
Los Angeles, California
Research Site
Whittier, California
Research Site
Jacksonville, Florida
Research Site
Orlando, Florida
Research Site
Athens, Georgia
Research Site
Atlanta, Georgia
Research Site
Fort Wayne, Indiana
Research Site
Baltimore, Maryland
Research Site
Bethesda, Maryland
Research Site
Rockville, Maryland
Research Site
Hattiesburg, Mississippi
Research Site
St Louis, Missouri
Research Site
Omaha, Nebraska
Research Site
Reno, Nevada
Research Site
Charlotte, North Carolina
Research Site
Winston-Salem, North Carolina
Research Site
Canton, Ohio
Research Site
Cleveland, Ohio
Research Site
Allentown, Pennsylvania
Research Site
York, Pennsylvania
Research Site
Houston, Texas
Research Site
Huntsville, Texas
Research Site
Kingwood, Texas
Research Site
Appleton, Wisconsin
Research Site
Buenos Aires, Argentina
Research Site
Pergamino, Argentina
Research Site
Rosario, Argentina
Research Site
Rosario, Argentina
Research Site
San Juan, Argentina
Research Site
Elizabeth Vale, Australia
Research Site
Lismore, Australia
Research Site
Murdoch, Australia
Research Site
South Brisbane, Australia
Research Site
Wollongong, Australia
Research Site
Charleroi, Belgium
Research Site
Ghent, Belgium
Research Site
Libramont-Chevigny, Belgium
Showing 40 of 191 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.